Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact
Autore:
Yamani, MH; Haji, SA; Starling, RC; Kelly, L; Albert, N; Knack, DL; Young, JB;
Indirizzi:
Cleveland Clin Fdn, Dept Cardiol, Kaufman Ctr Heart Failure, Cleveland, OH44195 USA Cleveland Clin Fdn Cleveland OH USA 44195 Failure, Cleveland, OH44195 USA
Titolo Testata:
AMERICAN HEART JOURNAL
fascicolo: 6, volume: 142, anno: 2001,
pagine: 998 - 1002
SICI:
0002-8703(200112)142:6<998:CODAMT>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
DILATED CARDIOMYOPATHY; INTRAVENOUS MILRINONE; INOTROPIC AGENTS; INFUSION; SECONDARY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
16
Recensione:
Indirizzi per estratti:
Indirizzo: Yamani, MH Cleveland Clin Fdn, Dept Cardiol, Kaufman Ctr Heart Failure, F25,9500 Euclid Ave, Cleveland, OH 44195 USA Cleveland Clin Fdn F25,9500 Euclid Ave Cleveland OH USA 44195 A
Citazione:
M.H. Yamani et al., "Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact", AM HEART J, 142(6), 2001, pp. 998-1002

Abstract

Background The use of parenteral positive inotropic agents still remains amajor component of therapy for patients with advanced decompensated congestive heart failure (CHF). However, no consensus guidelines have been developed for the appropriate selection of a first-line inotropic therapy. We sought to compare the clinical outcome and economic cost of dobutamine-based and milrinone-based therapy in patients with acute exacerbation of CHF. Methods and Results We retrospectively analyzed the outcome of 329 patients admitted to the heart failure unit with acute exacerbation of CHF. More patients were treated with dobutamine-based therapy (269/329, 81.7%) than with milrinone-based therapy (60/329, 18.3%). Both groups had similar baseline characteristics and similar hemodynamic profiles at baseline, with the exception of higher mean pulmonary arterial pressure in the milrinone group (47 mm Hg vs 42 mm Hg, P <.001). One hundred nine patients (40%) of the dobutamine group required parenteral nitroprusside for hemodynamic optimizationcompared with 11 patients (18%) in the milrinone group (P <.001). The use of parenteral nitroglycerin and dopamine was similar in both groups. There was no significant difference in the in-hospital mortality rate (dobutamine7.8% vs milrinone 10%) or clinical outcome between the 2 groups. However, the average direct drug cost per patient was significantly reduced in the dobutamine group compared with the milrinone group ($45 +/- $10 vs $1855 +/-$350, P < .0001). Conclusion Dobutamine-based therapy is an attractive approach for the treatment of decompensated advanced heart failure, achieving comparable clinical efficacy to milrinone with a significantly reduced economic cost.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/07/20 alle ore 05:11:45